ライフサイエンスコーパス: hydralazine

1 ltransferase expression (U0126, PD98059, and hydralazine).

2 Ci = 37 GBq) with or without the vasodilator hydralazine.

3 n hypoxia induced by the vasomodulator agent hydralazine.

4 y losartan or by the nonspecific vasodilator hydralazine.

5 en blood pressure is normalized with chronic hydralazine.

6 s induced by the ACE-independent vasodilator hydralazine.

7 s and the impact of isosorbide dinitrate and hydralazine.

8 Controls received water or hydralazine.

9 igration in vitro with losartan but not with hydralazine.

10 athway inhibitors including procainamide and hydralazine.

11 agen prolyl hydroxylase is a known target of hydralazine.

12 drug-induced lupus, similar to the effect of hydralazine.

13 ssure was returned to control by infusion of hydralazine (0.01 to 0.06 mg.kg(-1).min(-1)), RSNA retur

14 Hydralazine (10 mg/kg i.v.) increased the number of Fos-

15 nal studies, we found that acute addition of hydralazine (10 microM) to nitroglycerin-tolerant vessel

16 Coexposure to hydralazine (10-100 muM) strongly suppressed cell ATP lo

17 in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02).

18 either losartan (25 mg x kg(-1) x d(-1)) or hydralazine (15 mg x kg(-1) x d(-1)), both of which prev

19 ensive agents losartan (25 mg/kg per day) or hydralazine (15 mg/kg per day) inhibited this upregulati

20 etalol (48%), followed by nicardipine (15%), hydralazine (15%), and sodium nitroprusside (13%).

21 by blood pressure elevation, we administered hydralazine (250 mg/L) in the drinking water.

22 male apoE/eNOS DKO mice that were not given hydralazine (28.3+/-3.1%, n=9).

23 n, which was again blocked by treatment with hydralazine (382+/-18% and 150+/-30% of the control leve

24 RB; olmesartan, 5 mg/d) or a triple therapy (hydralazine 7.5 mg/d, reserpine 0.15 mg/d, and hydrochlo

25 s in forearm blood flow (CNP+, 93.0+/-14.8%; hydralazine+, 84.2+/-22.6%).

26 with aliskiren (a renin inhibitor), but not hydralazine (a smooth muscle relaxant), ameliorated coli

27 However, when RenTgMK mice were treated with hydralazine (a smooth muscle relaxant), the blood pressu

28 1) blocker; AT(1)), enalapril (an ACEI), and hydralazine (a vasodilator) were administered to spontan

29 lar decrease in SBP due to administration of hydralazine, a drug devoid of PDE inhibitory effect, did

30 eventable by normalizing blood pressure with hydralazine, a peripherally acting vasodilator.

31 Hydralazine activated more neurons than 2-deoxyglucose b

32 Thus, hydralazine activates the HIF pathway through inhibition

33 were treated with the antihypertensive agent hydralazine administered in the drinking water beginning

34 Hydralazine administration in animals caused a decrease

35 cerin patches (1.5 micrograms/kg/min x 3 d), hydralazine alone (10 mg/kg/d in drinking water), or hyd

36 CNP alone and hydralazine alone caused similar increases in forearm bl

37 (33%) of the 30 patients had been exposed to hydralazine and 3 (10%) had been exposed to propylthiour

38 ood pressure normalization by treatment with hydralazine and hydrochlorothiazide prevented angiotensi

39 Although the combined use of hydralazine and isosorbide dinitrate confers important c

40 ine alone (10 mg/kg/d in drinking water), or hydralazine and nitroglycerin.

41 s represents a novel mechanism of action for hydralazine and presents HIF as a potential target for t

42 The vasodilator hydralazine and the AT1 receptor antagonist losartan had

43 Hydralazine and zofenopril reduced mean arterial pressur

44 d propofol, fentanyl, metoprolol, lorazepam, hydralazine, and furosemide.

45 iple antihypertensive drugs (TRX; reserpine, hydralazine, and hydrochlorothiazide in drinking water;

46 Nitroprusside, adenosine, hydralazine, and nifedipine had no significant effect.

47 T cells treated with procainamide, hydralazine, and other Dnmt and ERK pathway inhibitors c

48 Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell DNA methylation

49 Procainamide and hydralazine are drugs that cause lupus in genetically pr

50 ood pressure was controlled with intravenous hydralazine as needed.

51 coinfusion of CNP at 500 pmol/min (n=8) and hydralazine at 10 microgram/min (n=8) (as a nonspecific

52 We have previously shown that hydralazine attacks carbonyl-adducted proteins in an "ad

53 clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice

54 largely catecholaminergic, were activated by hydralazine but not saline.

55 When given concomitantly with nitroglycerin, hydralazine completely prevented the development of nitr

56 tor enalapril, but not the anti-hypertensive hydralazine, decreased pulmonary neutrophil recruitment

57 ering blood pressure to the same degree with hydralazine did not abolish the upregulation of TR mRNA

58 In vitro, hydralazine did not inhibit DNMT activity.

59 Additionally, hydralazine did not reduce expression levels of either t

60 Hydralazine did not significantly inhibit the effect of

61 the combination of isosorbide dinitrate and hydralazine differs in black and white heart failure coh

62 Reduction of hypertension with hydralazine does not change the prevalence of aggression

63 Hydralazine dose-dependently inhibited PHD activity and

64 We demonstrate that hydralazine extends healthy lifespan ( 25%) in wild type

65 dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients with heart failure (HF

66 dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death

67 with Ang II receptor antagonist losartan or hydralazine for 12 wk.

68 onths of therapy with either zofenopril (Z), hydralazine (H), or water (W).

69 c cross clamp: phentolamine mesylate (PM) or hydralazine (H).

70 One of the patients exposed to hydralazine had also been exposed to allopurinol.

71 Hydralazine has been shown to reduce mortality in patien

72 in vivo models, we go on to demonstrate that hydralazine has neuroprotective properties against endog

73 upus or treated with the lupus-inducing drug hydralazine have defective ERK phosphorylation.

74 rt failure rats, to test the hypothesis that hydralazine (HYD) alone or in combination with nitroglyc

75 mpared the effects of procainamide (Pca) and hydralazine (Hyd) with those of structural analogs, to d

76 dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H) significantly decrea

77 In 2005, the combination of hydralazine hydrochloride and isosorbide dinitrate was a

78 n (FDA) approval of the fixed combination of hydralazine hydrochloride, 37.5 mg, and isosorbide dinit

79 trials showed little or no overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mo

80 ally mixed patient populations that compared hydralazine hydrochloride-isosorbide dinitrate with plac

81 d black patients with heart failure who took hydralazine hydrochloride-isosorbide dinitrate with stan

82 Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in all-male study cohor

83 Treatment with hydralazine in rabbits not receiving nitroglycerin signi

84 RF, CRF antagonist D-PheCRF12-41 and chronic hydralazine in stress-induced cardiovascular responses.

85 Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a d

86 the effect of lowering blood pressure using hydralazine in this diabetic eNOSKO mouse model.

87 In sponge angiogenesis assays, hydralazine increased stromal cell infiltration and bloo

88 In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissu

89 ification, is implicated in procainamide and hydralazine induced lupus, as well as idiopathic lupus.

90 Hydralazine induced rapid and transient expression of HI

91 by FG-labeled RVLM neurons after 2 hours of hydralazine-induced hypotension (to 73 +/- 2 mm Hg) in c

92 unanesthetized rats subjected to 2 hours of hydralazine-induced hypotension contained tenfold more c

93 Hydralazine-induced lupus could be caused in part by ind

94 tribute to the development of idiopathic and hydralazine-induced lupus through effects on T cell DNA

95 Instead, hydralazine inhibited ERK pathway signaling, thereby dec

96 tive DNA methyltransferase (Dnmt) inhibitor, hydralazine inhibits ERK pathway signaling thereby decre

97 Here, we report that the FDA approved drug hydralazine is a bona fide activator of the NRF2/SKN-1 s

98 xed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved clinical outcomes in the

99 In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart fail

100 none in 2003 and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005.

101 enalapril decreased overall mortality versus hydralazine/isosorbide dinitrate (p < 0.035) in V-HeFT I

102 ne antagonists in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligi

103 razosin and placebo therapy in V-HeFT I, and hydralazine/isosorbide dinitrate was compared with enala

104 cular ejection fraction >35%, treatment with hydralazine/isosorbide dinitrate was compared with prazo

105 ers, beta-blockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants.

106 all mortality and sudden death compared with hydralazine/isosorbide dinitrate.

107 sed agents include nitroprusside, diazoxide, hydralazine, labetalol, esmolol, nicardipine, nifedipine

108 and hydralazine-treated cells revealed that hydralazine likely promoted Hsp90 migration from cytosol

109 Our data suggest that hydralazine may be a viable candidate for the treatment

110 y hydralazine, providing a mechanism whereby hydralazine may prevent tolerance.

111 We sought to determine mechanisms whereby hydralazine may prevent tolerance.

112 We show that hydralazine-mediated lifespan extension is SKN-1 depende

113 culprits receiving attention of late, namely hydralazine, minocycline, propylthiouracil (PTU) and lev

114 Hydralazine, minocycline, propylthiouracil and levamisol

115 ion, has been observed during treatment with hydralazine, nifedipine and ACE inhibitors.

116 short-term administration of nitroprusside, hydralazine, nifedipine or an angiotensin-converting enz

117 ed beta-blocker use, aldosterone-antagonist, hydralazine/nitrate; p < 0.05) except warfarin in patien

118 ers, beta-blockers, aldosterone antagonists, hydralazine/nitrates, statin therapy, and warfarin), use

119 When hypotension was induced with hydralazine, NK3-R internalization was observed within 5

120 Long-term administration of hydralazine normalized blood pressure in NOS3(-/-) mice,

121 The effect of hydralazine on DNMT was tested in vitro using enzyme inh

122 ixed combination of isosorbide dinitrate and hydralazine on the primary composite end point (p = 0.01

123 Murine T cells treated with hydralazine or an ERK pathway inhibitor were injected in

124 ve a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy f

125 now many reports that treatment with either hydralazine or propylthiouracil is associated with ANCA-

126 associated, especially following exposure to hydralazine or propylthiouracil.

127 medulla, in Sprague Dawley rats treated with hydralazine or saline.

128 e mice BH(4) (5 mg/d), but not treating with hydralazine or tetrahydroneopterin, improved cardiac BH(

129 treatment with either enalapril, furosemide, hydralazine, or losartan were all effective in reducing

130 Hydralazine prevented the development of hypertension in

131 Hydralazine prevented the hypertension and abrogated the

132 we determined the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previousl

133 ver, there have been reports suggesting that hydralazine, propylthiouracil, and several other drugs m

134 increased pulsatile load in SHR treated with hydralazine, provided a hemodynamic basis for the differ

135 fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with a

136 the activity of this oxidase is inhibited by hydralazine, providing a mechanism whereby hydralazine m

137 Compared with water or hydralazine, RAAS inhibition significantly increased the

138 Although the nucleophilic vasodilatory drug hydralazine readily traps such species under "test-tube"

139 Hydralazine reproduces the lupus ERK pathway signaling a

140 (not Wistar-Furth rats) being treated with a hydralazine-reserpine-hydrochlorothiazide regimen.

141 Most strikingly, hydralazine selectively boosted the levels of cytoskelet

142 sion of established atherosclerosis, whereas hydralazine showed no benefit despite similar decrease i

143 in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0

144 te group than in the nimodipine group needed hydralazine to control blood pressure (54.3 percent vs.

145 The ability of hydralazine to inhibit vascular .O2- anion production re

146 ms were due to hypertension, we administered hydralazine to male apoE/eNOS DKO mice to reduce blood p

147 ated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed defective glu

148 of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure includ

149 +) lupus T cells as well as procainamide and hydralazine treated T cells, and contributes to excessiv

150 Biochemical fractionation of acrolein- and hydralazine-treated cells revealed that hydralazine like

151 4(+) T cells from patients with lupus and in hydralazine-treated cells.

152 Four of 11 hydralazine-treated male apoE/eNOS DKO mice developed ab

153 None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in

154 ignificantly reduced in samples derived from hydralazine-treated SHR as compared with those from hydr

155 Hydralazine-treated SHR had increased characteristic imp

156 CRF given to hydralazine-treated SHRLJ did not unmask a bradycardia.

157 and CD70 overexpression similar to lupus and hydralazine-treated T cells.

158 Hydralazine-treated, normotensive male apoE/eNOS DKO mic

159 zine-treated SHR as compared with those from hydralazine-treated, or untreated WKY.

160 Hydralazine treatment (4-5 weeks) prevented the developm

161 ncta in the NTS was significantly reduced by hydralazine treatment in the SHR model.

162 Hydralazine treatment significantly blocked the developm

163 enoprotective effects were not observed with hydralazine treatment, despite a similar antihypertensiv

164 trengthened by similar results obtained with hydralazine treatment, which inhibits expression of DNA

165 The vasodilator hydralazine, used clinically in cardiovascular therapy,

166 In Group I, class I antiarrhythmic drugs and hydralazine vasodilator therapy were routinely allowed.

167 yte width increased after MI, whether or not hydralazine was administered.

168 Hydralazine was ineffective in reducing cell size but ar

169 ying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate tumor perfusion befo

170 , some beta-blockers, and the combination of hydralazine with nitrates have improved survival.